|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
EP0817775B1
(en)
|
1995-03-30 |
2001-09-12 |
Pfizer Inc. |
Quinazoline derivatives
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
DK0892789T4
(da)
|
1996-04-12 |
2010-04-06 |
Warner Lambert Co |
Irreversible inhibitorer af tyrosin kinaser
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
ZA986729B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
HU230302B1
(hu)
*
|
2000-10-20 |
2015-12-28 |
Eisai R&D Management Co., Ltd. |
Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
|
|
SI2392564T1
(sl)
*
|
2003-09-26 |
2014-02-28 |
Exelixis, Inc. |
c-Met modulatorji in postopki uporabe
|
|
EP1871417B1
(en)
|
2005-04-15 |
2013-09-11 |
Precision Biologics, Inc. |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
|
|
PL2439273T3
(pl)
|
2005-05-09 |
2019-08-30 |
Ono Pharmaceutical Co., Ltd. |
Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
|
|
CA2627598C
(en)
*
|
2005-11-07 |
2013-06-25 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
|
AU2009303602B2
(en)
*
|
2008-10-14 |
2012-06-14 |
Sunshine Lake Pharma Co., Ltd. |
Compounds and methods of use
|
|
CA2995880C
(en)
|
2009-01-16 |
2021-01-05 |
Exelixis, Inc. |
Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
EP2214019A1
(en)
|
2009-01-28 |
2010-08-04 |
Externautics S.p.A. |
Tumor markers and methods of use thereof
|
|
EP2213686A1
(en)
|
2009-01-28 |
2010-08-04 |
Externautics S.p.A. |
Tumor markers and methods of use thereof
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
EP2494362B1
(en)
|
2009-10-26 |
2016-06-08 |
Externautics S.p.A. |
Prostate tumor markers and methods of use thereof
|
|
US10288617B2
(en)
|
2009-10-26 |
2019-05-14 |
Externautics Spa |
Ovary tumor markers and methods of use thereof
|
|
US20120322075A1
(en)
|
2009-10-26 |
2012-12-20 |
Externautics S.P.A. |
Lung Tumor Markers and Methods of Use Thereof
|
|
WO2011051276A1
(en)
|
2009-10-26 |
2011-05-05 |
Externautics S.P.A. |
Colon and rectal tumor markers and methods of use thereof
|
|
US20130017546A1
(en)
|
2009-10-26 |
2013-01-17 |
Externautics S.P.A. |
Breast Tumor Markers and Methods of Use Thereof
|
|
US20120070368A1
(en)
*
|
2010-04-16 |
2012-03-22 |
Exelixis, Inc. |
Methods of Using C-Met Modulators
|
|
EP2383578A1
(en)
|
2010-04-30 |
2011-11-02 |
Externautics S.p.A. |
Tumor marker and methods of use thereof
|
|
SG187064A1
(en)
*
|
2010-07-14 |
2013-02-28 |
Zhejiang Beta Pharma Inc |
NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
|
|
TWI619495B
(zh)
|
2010-07-16 |
2018-04-01 |
艾克塞里克斯公司 |
Ｃ-ｍｅｔ調節劑醫藥組合物
|
|
US8664244B2
(en)
*
|
2010-09-12 |
2014-03-04 |
Advenchen Pharmaceuticals, LLC |
Compounds as c-Met kinase inhibitors
|
|
HUE045810T2
(hu)
|
2010-09-27 |
2020-01-28 |
Exelixis Inc |
MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
|
|
CN102093421B
(zh)
*
|
2011-01-28 |
2014-07-02 |
北京康辰药业有限公司 |
一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
|
KR20230158644A
(ko)
|
2011-02-10 |
2023-11-20 |
엑셀리시스, 인코포레이티드 |
퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
|
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
|
US20140179736A1
(en)
|
2011-05-02 |
2014-06-26 |
Exelixis, Inc. |
Method of Treating Cancer and Bone Cancer Pain
|
|
CN102408411B
(zh)
*
|
2011-09-19 |
2014-10-22 |
北京康辰药业股份有限公司 |
一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
|
WO2013043840A1
(en)
|
2011-09-22 |
2013-03-28 |
Exelixis, Inc. |
Method for treating osteoporosis
|
|
JP6208140B2
(ja)
|
2011-10-20 |
2017-10-04 |
エクセリクシス， インク． |
キノリン誘導体の調製プロセス
|
|
CN104159585A
(zh)
|
2011-11-08 |
2014-11-19 |
埃克塞里艾克西斯公司 |
用于治疗癌症的met和vegf双重抑制剂
|
|
BR112014011008A2
(pt)
|
2011-11-08 |
2018-06-19 |
Exelixis Inc |
método de quantificação de tratamento de câncer
|
|
JP2015515988A
(ja)
|
2012-05-02 |
2015-06-04 |
エクセリクシス， インク． |
溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
|
|
WO2014039971A1
(en)
|
2012-09-07 |
2014-03-13 |
Exelixis, Inc. |
Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
|
|
MX370848B
(es)
|
2012-10-04 |
2020-01-08 |
Dana Farber Cancer Inst Inc |
Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso.
|
|
EP2970126B1
(en)
|
2013-03-15 |
2019-03-06 |
Exelixis, Inc. |
Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
|
|
WO2014165786A1
(en)
|
2013-04-04 |
2014-10-09 |
Exelixis, Inc. |
Cabozantinib dosage form and use in the treatment of cancer
|
|
KR20150138268A
(ko)
|
2013-04-04 |
2015-12-09 |
엑셀리시스, 인코포레이티드 |
암을 치료하기 위한 약물 병용요법
|
|
DK2992017T3
(da)
|
2013-05-02 |
2021-01-25 |
Anaptysbio Inc |
Antistoffer rettet mod programmeret død-1 (pd-1)
|
|
US10359428B2
(en)
|
2013-06-14 |
2019-07-23 |
Externautics S.P.A. |
Tumor marker, monoclonal antibodies and methods of use thereof
|
|
IL292510A
(en)
|
2013-11-05 |
2022-06-01 |
Cognate Bioservices Inc |
Combinations of checkpoint inhibitors and cancer drugs
|
|
EP3738952A1
(en)
|
2014-02-14 |
2020-11-18 |
Exelixis, Inc. |
Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
|
|
EP3119476A1
(en)
|
2014-03-17 |
2017-01-25 |
Exelixis, Inc. |
Dosing of cabozantinib formulations
|
|
ES2874875T3
(es)
|
2014-04-25 |
2021-11-05 |
Exelixis Inc |
Procedimiento de tratamiento de adenocarcinoma de pulmón
|
|
EP3174854B1
(en)
|
2014-07-31 |
2022-08-24 |
Exelixis, Inc. |
Method of preparing fluorine-18 labeled cabozantinib and its analogs
|
|
CN106573042A
(zh)
|
2014-08-05 |
2017-04-19 |
埃克塞里艾克西斯公司 |
治疗多发性骨髓瘤的药物组合
|
|
CN104817497B
(zh)
*
|
2015-03-20 |
2017-03-08 |
南京众睿缘生物科技有限公司 |
一种炔代喹啉衍生物及其制备方法和用途
|
|
CN106279147A
(zh)
|
2015-05-21 |
2017-01-04 |
中国科学院上海药物研究所 |
一种吡啶并氮杂环化合物及其制备方法和用途
|
|
US20170342033A1
(en)
*
|
2015-06-29 |
2017-11-30 |
Ontogenesis, Llc |
Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
|
|
US20180009758A1
(en)
*
|
2015-06-29 |
2018-01-11 |
Ontogenesis, Llc |
Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
|
|
CN109069499A
(zh)
|
2016-04-15 |
2018-12-21 |
埃克塞里艾克西斯公司 |
使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
|
|
US20210030737A1
(en)
|
2016-04-19 |
2021-02-04 |
Exelixis, Inc. |
Triple Negative Breast Cancer Treatment Method
|
|
CN105797123A
(zh)
*
|
2016-05-18 |
2016-07-27 |
王超 |
一种治疗不孕不育的中药组合物
|
|
CN106400155A
(zh)
*
|
2016-08-31 |
2017-02-15 |
飞佛特种纺织品（宁波）有限公司 |
一种防老化阳光面料
|
|
CN107235896B
(zh)
*
|
2016-09-13 |
2019-11-05 |
上海翔锦生物科技有限公司 |
酪氨酸激酶抑制剂及其应用
|
|
CA3038500A1
(en)
|
2016-09-27 |
2018-04-05 |
Andrea B. Apolo |
Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
EP3570840A1
(en)
|
2017-01-20 |
2019-11-27 |
Exelixis, Inc. |
Combinations of cabozantinib and atezolizumab to treat cancer
|
|
US10800741B2
(en)
*
|
2017-02-07 |
2020-10-13 |
Ancureall Pharmaceutical (Shanghai) Co., Ltd. |
Quinoline compound, preparation method and medical use therefor
|
|
EA039654B1
(ru)
|
2017-05-26 |
2022-02-22 |
Экселиксис, Инк. |
Кристаллические твердые формы солей n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и методы использования
|
|
BR112019025110A2
(pt)
|
2017-06-09 |
2020-09-01 |
Exelixis, Inc. |
formas de dosagem líquida para tratar câncer
|
|
WO2019125798A1
(en)
|
2017-12-20 |
2019-06-27 |
Angex Pharmaceutical, Inc. |
Carbamate and urea compounds as multikinase inhibitors
|
|
US20190262330A1
(en)
|
2017-12-21 |
2019-08-29 |
Exelixis, Inc. |
Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
|
|
WO2019148036A1
(en)
*
|
2018-01-26 |
2019-08-01 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
|
AU2019212800B2
(en)
*
|
2018-01-26 |
2024-05-23 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
|
CN117624045A
(zh)
*
|
2018-01-26 |
2024-03-01 |
埃克塞里艾克西斯公司 |
用于治疗激酶依赖性病症的化合物
|
|
CN113329790A
(zh)
*
|
2018-12-13 |
2021-08-31 |
埃克塞里艾克西斯公司 |
激酶抑制剂的结晶形式和盐形式
|
|
CN113710322A
(zh)
*
|
2019-01-25 |
2021-11-26 |
埃克塞里艾克西斯公司 |
用于治疗激酶依赖性病症的化合物
|
|
BR112021024300A2
(pt)
*
|
2019-06-03 |
2022-01-11 |
Exelixis Inc |
Formas de sais cristalinas de um inibidor de quinase
|
|
AR119069A1
(es)
*
|
2019-06-04 |
2021-11-24 |
Exelixis Inc |
Compuestos para el tratamiento de trastornos dependientes de quinasas
|
|
JP2023524692A
(ja)
*
|
2020-04-30 |
2023-06-13 |
エグゼリクシス， インコーポレイテッド |
キナーゼ阻害剤を調製するためのプロセス
|
|
CR20230052A
(es)
*
|
2020-07-31 |
2023-04-11 |
Exelixis Inc |
Combinaciones para el tratamiento de cáncer.
|
|
EP4240333A1
(en)
*
|
2020-11-05 |
2023-09-13 |
Exelixis, Inc. |
Pharmaceutical compositions of a kinase inhibitor
|
|
AR127561A1
(es)
*
|
2021-11-03 |
2024-02-07 |
Exelixis Inc |
Compuestos para el tratamiento de trastornos dependientes de cinasas
|
|
AU2022420610A1
(en)
*
|
2021-12-22 |
2024-06-27 |
Exelixis, Inc. |
Crystalline forms and salt forms of a kinase inhibitor
|